AbbVie Inc (ABBV) : Vision Capital Management reduced its stake in AbbVie Inc by 49.94% during the most recent quarter end. The investment management company now holds a total of 67,293 shares of AbbVie Inc which is valued at $4,521,417 after selling 67,136 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.AbbVie Inc makes up approximately 1.68% of Vision Capital Management’s portfolio.
Other Hedge Funds, Including , Nomura Asset Management Co Ltd reduced its stake in ABBV by selling 50,552 shares or 9.13% in the most recent quarter. The Hedge Fund company now holds 503,094 shares of ABBV which is valued at $33,802,886. AbbVie Inc makes up approx 0.61% of Nomura Asset Management Co Ltd’s portfolio.Aviance Capital Partners reduced its stake in ABBV by selling 1,789 shares or 4.74% in the most recent quarter. The Hedge Fund company now holds 35,946 shares of ABBV which is valued at $2,415,212. AbbVie Inc makes up approx 0.85% of Aviance Capital Partners’s portfolio.Jacobus Wealth Management reduced its stake in ABBV by selling 3,117 shares or 5.01% in the most recent quarter. The Hedge Fund company now holds 59,147 shares of ABBV which is valued at $3,935,641. AbbVie Inc makes up approx 1.17% of Jacobus Wealth Management’s portfolio.Sippican Capital Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 2,900 additional shares and now holds a total of 10,443 shares of AbbVie Inc which is valued at $677,751. AbbVie Inc makes up approx 0.77% of Sippican Capital Advisors’s portfolio.
AbbVie Inc closed down -0.1 points or -0.15% at $64.51 with 50,99,249 shares getting traded on Monday. Post opening the session at $64.84, the shares hit an intraday low of $64.19 and an intraday high of $65.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.